Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

BPC-157 and Sermorelin Stack: When to Pick One Over Both

By
Published Updated Last reviewed
12 linked public sourcesEditorial, sourcing, and corrections policy

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Key numbers

  • 30 patientsTotal patients in human orthopaedic studies of this peptide, per a 2026 review rated very low certaintySource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 110 childrenChildren enrolled in the main open-label sermorelin trial, 86 of whom were evaluableSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 1-yearLength of the pediatric sermorelin trial that saw no adverse changes in biochemistry or hormone testsSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07

At a glance

  • BPC-157 / Not FDA-approved [1]
  • Sermorelin / Geref approvals withdrawn June 18, 2009 [2]
  • BPC-157 human evidence / 3 orthopaedic studies, 30 patients, very low certainty [3]
  • WADA / Both prohibited at all times [5]

What each peptide is

BPC-157 is a synthetic 15-amino-acid peptide from a protein first isolated in human gastric juice [1]. It is not FDA-approved; FDA's July 2026 review found no approved product containing it in any country it searched [1]. Its mechanism in people is not established, and FDA says its molecular targets have not been identified [1]. A 2026 systematic review of orthopaedic and regenerative use found 3 human studies, 30 patients total, with very low certainty of evidence [3]. FDA says there is insufficient clinical safety information to characterize its safety profile [1].

Sermorelin is a 29-amino-acid growth hormone-releasing hormone analogue, not growth hormone itself [6]. Geref was approved only for a pituitary growth hormone test and for treating idiopathic growth hormone deficiency in children with growth failure; it was not approved for adults, anti-aging, weight loss or athletic performance [2]. The maker discontinued it in 2008, FDA withdrew the approvals on June 18, 2009, and FDA later determined it was not withdrawn for safety or effectiveness reasons [2]. No sermorelin product is FDA-approved today [2]. The main open-label trial enrolled 110 children, 86 evaluable, and height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months [4].

Dr. Alex Tatem on why sermorelin helps sleep but not muscle

Dr. Alex Tatem argues that sermorelin is one of the more defensible peptides, mainly because its sleep benefit has real human trial data behind it. He explains that sermorelin is only a fragment of growth hormone releasing hormone, so it asks the pituitary to release its own growth hormone rather than delivering the hormone itself. In his view this keeps the body's feedback loops in place, which limits overdosing but also means the drug does nothing if the pituitary is depleted. He is skeptical of muscle gains, noting that growth hormone tends to add water and connective tissue rather than contractile tissue. He also says most commercial doses sit far below the amounts that showed effects in trials, so people who feel nothing may simply be underdosed.

Who is speaking?

Dr. Alex Tatem. Host of the Dr. Alex Tatem channel, as the channel presents him Background

Episode notes and full video

Is there evidence for the stack?

The human studies of BPC-157 described by FDA and in the 2026 review did not pair it with sermorelin, and the sermorelin studies did not include BPC-157 [1][3][4][7]. FDA says BPC-157's reported protective effects come from rat studies [1]. In a short physiology study, sermorelin raised growth hormone and IGF-I in older men [7]. Neither finding shows that combining the two improves healing, performance or safety. Neither product has a current approved dose [1][2].

When might one be chosen over both?

For tissue repair, BPC-157 has only very low-certainty human evidence [3], while sermorelin's main treatment trial measured growth in children with growth hormone deficiency, not tissue repair [4]. Nothing in that evidence shows that one of them, or both, works better. For athletes subject to WADA rules, BPC-157 is prohibited at all times under S0 and sermorelin under S2.2.4 [5].

The practical differences come down to regulatory status:

  • Approval: neither is approved today [1][2].
  • Compounding: BPC-157 is not on FDA's list for state-licensed pharmacies and physicians, and FDA's category 1 policy does not cover it [8]. HHS's October 2026 enforcement-discretion policy for BPC-157 is a draft, non-binding statement, not an approval [9][10]. Sermorelin is not in any category on that state-licensed pharmacy list and is not one of the six peptides in the HHS draft [8][10]. Compounded drugs are not FDA-approved [11].
  • Safety: FDA says BPC-157 safety information is insufficient [1]. The 1-year pediatric sermorelin trial saw no adverse changes in general biochemistry or hormone tests [4].

For more information about sermorelin, see sermorelin.

Questions worth asking

Choose the questions you want to keep

Frequently asked questions

Is the BPC-157 and sermorelin stack FDA-approved?
No. BPC-157 is not FDA-approved, and the only sermorelin approvals were for Geref, withdrawn in 2009. No sermorelin product is FDA-approved today, and compounded drugs are not FDA-approved [1][2][11].
Which one is better for tissue repair?
Neither has been shown to be better. BPC-157 has very low-certainty human evidence from three small studies [3]. Sermorelin's main treatment trial measured growth in children with growth hormone deficiency, not tissue repair [4].
Are BPC-157 and sermorelin allowed in sport?
No. WADA names BPC-157 in S0 and sermorelin in S2.2.4; both are prohibited at all times, in and out of competition [5].

What people actually ask

Can I stack Sermorelin and BPC-157 together?

No evidence shows that combining them helps. The human studies of BPC-157 did not pair it with sermorelin, and the sermorelin studies did not include BPC-157. Neither finding shows the combination improves healing, performance or safety, and neither product has a current approved dose.

Is there anything better than Sermorelin?

Nothing in the evidence shows that one of them, or both, works better, including for tissue repair. Sermorelin's main treatment trial measured growth in children with growth hormone deficiency, not tissue repair. Neither is FDA-approved today.

Is there something better than BPC-157?

Not established. For tissue repair, BPC-157 has only very low-certainty human evidence from 3 human studies with 30 patients total, and FDA says its safety information is insufficient. Nothing shows that sermorelin, or both together, works better.

References

  1. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  2. Federal Register :: Request Access. Federal Register :: Request Access
  3. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety
  4. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group
  5. World Anti-Doping Agency. World Anti-Doping Agency
  6. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
  7. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
  8. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  9. Official web page. Official web page
  10. Official web page. Official web page
  11. Compounding and the FDA: Questions and Answers | FDA. Compounding and the FDA: Questions and Answers | FDA
  12. Dr. Alex Tatem. Sermorelin: The "Safer HGH" Has One Huge Problem. Accessed 2026-11-11.
Evidence overview for BPC-157 and Sermorelin Stack: When to Pick One Over Both